Julius Clinical and Peachtree BioResearch Solutions form Global CRO Powerhouse

Deal News | May 14, 2025 | Ampersand Capital Partners

Julius Clinical and Peachtree BioResearch Solutions form Global CRO Powerhouse

Julius Clinical, a Netherlands-based CRO, and Peachtree BioResearch Solutions, a U.S.-based CNS specialized CRO, announced their merger to form an integrated global CRO. This strategic merger leverages a long-term partnership, expanding the combined entity's reach and capabilities across Europe and North America. The merger enhances their proficiency in conducting Phase I-III clinical trials particularly in CNS, cardio-metabolic, renal, and rare diseases. Supported by Ampersand Capital Partners, this new entity aims to deliver end-to-end clinical research services efficiently while maintaining scientific excellence and operational prowess. The merger reflects a strategic alignment intended to meet increasing complexities in clinical research and serve clients in the pharmaceutical, biotech, and medical device sectors more robustly.

Sectors

  • Clinical Research Organization (CRO)
  • Life Sciences
  • Private Equity

Geography

  • Netherlands – Julius Clinical is headquartered in Zeist, Netherlands, marking significant relevance for the regional presence and expansion.
  • United States – Peachtree BioResearch Solutions is based in Georgia, U.S., emphasizing its role in expanding operations and scientific excellence in North America.
  • Global – The merger creates a global entity with services available across Europe and North America, reflecting a strategic international expansion.

Industry

  • Clinical Research Organization (CRO) – The merger forms a large integrated global Contract Research Organization, enhancing capabilities in CNS, cardio-metabolic, and rare diseases.
  • Life Sciences – Julius Clinical and Peachtree BioResearch specialize in life sciences, offering clinical trials and research specifically in pharmaceuticals and biotechnology.
  • Private Equity – Ampersand Capital Partners is a private equity firm supporting the merger through its investment in Julius Clinical, highlighting its role in healthcare investments.

Financials

  • $3 billion – Assets under management by Ampersand Capital Partners, which supports Julius Clinical in its operations and expansions.

Participants

NameRoleTypeDescription
Julius ClinicalMerging CompanyCompanyA leading CRO based in the Netherlands specializing in CNS, cardio-metabolic, renal, and rare diseases research.
Peachtree BioResearch SolutionsMerging CompanyCompanyA U.S.-based CRO specializing in CNS, offering clinical development services for biotech, pharmaceutical, and medical device sectors.
Ampersand Capital PartnersPrivate Equity FirmCompanyA private equity firm that invests in healthcare, supporting Julius Clinical in its growth and strategic endeavors.
Martijn WallertCEO of Julius ClinicalPersonLeader of Julius Clinical, driving the merger and international expansion strategy.
Kristy NicholsCEO of Peachtree BioResearch SolutionsPersonLeader of Peachtree BioResearch Solutions, fostering the merger and preservation of its personalized service approach.